文献速递浆细胞疾病

托珠单抗预防双特异性抗体治疗多发性骨髓瘤患者的细胞因子释放综合征

Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies.
PubMed 文献 · Blood Adv · 2025-01-01

本研究在真实世界中对119例接受双特异性抗体治疗的多发性骨髓瘤患者,在首剂双特异性抗体前给予单剂托珠单抗预防。最佳总缓解率为65.7%(二项95%CI 55.8-74.7),细胞因子释放综合征(CRS)总发生率为10.1%(95%CI 5.3-17),免疫效应细胞相关神经毒性综合征(ICANS)总发生率为5.9%(95%CI 2.4-11.7)。作者认为托珠单抗作为预防而非反应性措施可能有效预防CRS而不影响疗效。

要点

  • 首剂双特异性抗体前单剂托珠单抗预防,CRS总发生率10.1%(95%CI 5.3-17)。
  • CRS事件12例中10例为1级,无3级CRS事件发生。
  • ICANS总发生率5.9%(95%CI 2.4-11.7),与未预防性使用托珠单抗时相似。

核心结论

  • 真实世界证据结果提示,托珠单抗作为预防而非反应性措施可能有效预防CRS而不影响疗效。

研究设计与样本

  • 在真实世界环境中,对119例接受双特异性抗体(包括B细胞成熟抗原×CD3和G蛋白偶联受体C类第5组成员D×CD3靶向抗体)治疗的多发性骨髓瘤患者,在首剂双特异性抗体前给予单剂托珠单抗。

主要发现

  • 最佳总缓解率为65.7%(二项95%CI 55.8-74.7)。
  • CRS总发生率为10.1%(95%CI 5.3-17);特立妥单抗、埃纳妥单抗、linvoseltamab和塔奎妥单抗的CRS发生率分别为8.9%、12.5%、0%和13%。
  • ICANS总发生率为5.9%(95%CI 2.4-11.7),较低但与未预防性使用托珠单抗时相似。
  • 12例CRS事件中10例限于1级;无3级CRS事件,且未因CRS给予额外剂量托珠单抗或皮质类固醇。

临床怎么用

  • 作者认为托珠单抗作为预防而非反应性措施可能有效预防CRS而不影响疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bispecific antibodies for treatment for multiple myeloma are highly effective but commonly cause cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Emerging data indicate that prophylactic tocilizumab may reduce CRS, without impacting efficacy. We administered a single dose of tocilizumab before the first dose of bispecific antibodies to 119 patients to determine the impact on CRS in a real-world setting including B-cell maturation antigen × CD3- and G-protein-coupled receptor class C group 5 member D × CD3-targeted antibodies. The best overall response rate was 65.7% (binomial 95% confidence interval [CI], 55.8-74.7). We observed a low overall rate of CRS (10.1%; 95% CI, 5.3-17). For teclistamab, elranatamab, linvoseltamab, and talquetamab individually, the CRS rate was 8.9%, 12.5%, 0%, and 13%, respectively. The overall rate of ICANS (5.9%; 95% CI, 2.4-11.7) was low but similar to rates without prophylactic tocilizumab. CRS was limited to grade 1 for 10 of 12 events. There were no grade 3 CRS events, and no additional doses of tocilizumab or corticosteroids were given for CRS. Our real-world evidence results suggest that tocilizumab may be effective as a preventive, rather than reactive, measure to prevent CRS without compromising efficacy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kowalski A, Lykon J, Diamond B, et al. Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies. Blood Adv. 2025. PMID: 40590849. doi:10.1182/bloodadvances.2025016911

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。